<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gater, Laura</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Grant, Maria</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Diabetic Retinopathy — Diagnostic and Treatment Novelties</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-24</style></pages><abstract><style  face="normal" font="default" size="100%">Blocking growth hormone or insulin-like growth factor 1 (IGF-1) are possible treatments for diabetic retinopathy (DR). GH and IGF-1 antagonists can produce significant reduction in neovascularization and reduction in the number of patients progressing to blindness.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>